After Karuna"s acquisition, former CEO lands new gig at Cambridge biotech

Cambridge startup Relay Therapeutics closed a $400 million funding round Thursday, led by a Japanese telecommunications giant that has recently started investing in local biotech and tech companies. Relay uses computer models to study how protein.....»»

Biotechnology company TurtleTree has secured its first commercial customer — an endurance-sports supplement company......»»

The deal, which could pay the Peninsula company a $100 million upfront and up to $370 million per target, is the third aimed at assembling CRISPR's components in the body......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Seattle-based biotech company LifeSpan BioSciences, known as LSBio, has acquired United Kingdom-based Absolute Antibody Ltd. and its sister company, Boston-based Kerafast Inc. The acquisition adds a range of reagents and antibody services to .....»»

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) read more.....»»

A Cambridge startup that already had $147 million in its pocket at the end of last year is returning the Paycheck Protection Program loan it received following nationwide criticism of how the funds were awarded......»»

Years before Cynthia Cassandro joined Cambridge biotech Voyager Therapeuti.....»»

One of the biotech industry’s up-and-coming gene therapy companies is further delaying its plans for a U.S. drug launch due to disagreements with FDA officials and the COVID-19 pandemic.  Cambridge's Bluebird bio (Nasdaq: BLUE) has been at the .....»»

A Cambridge biotech raised $75 million in a downsized IPO as the coronavirus, also known as COVID-19, has caused the stock markets to crumble. Imara Inc. (Nasdaq: IMRA) closed its IPO this week at the low end of its goal, raising $75 million after .....»»

After more than a month of covert work, the Cambridge biotech disclosed Wednesday that it's developing a coronavirus treatment with a California biotech startup......»»

A St. Louis biotechnology startup has acquired a local research laboratory in a move to accelerate its path to commercialization. Pluton Biosciences said Wednesday it has acquired Microbe Inotech Laboratories (MiL), a commercial research and testing.....»»

The FDA has approved the first-ever commercial cancer treatment from Cambridge biotech Epizyme Inc. Just a few years ago, Epizyme had given up on its potential cancer treatment and sold it to a Japanese drug company. On Thursday, the FDA approved the .....»»

A young biotech startup hoping to map out the actions of cells throughout the body has signed its second major drug development partner with biotech giant Biogen......»»

FDA approves Cambridge biotech"s first-ever drug for cancer.....»»

PGIM Real Estate Finance has arranged $240 million acquisition financing for the Bank of America Tower, a 35-story Class ‘AA’.....»»

Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month......»»

A gene therapy invented at Nationwide Children's Hospital just landed a licensing deal worth as much as $2.8 billion for a Boston biotech, and now the company's Columbus office will play a big role in getting the treatment to the market. Sarepta Th.....»»

Cambridge Savings Bank’s holding company has agreed to buy Melrose Bank’s parent for approximately $58 million, moving into a market just outside its current brick-and-mortar footprint. The deal comes two years after Melrose became eligible to b.....»»